

# PARTNERING WITH **SERVIER**

**SERVIER**   
*moved by you*



**SERVIER**   
*moved by you*

**Your strategic partner**

**We are a private, independent pharmaceutical company, governed by a foundation.**

Our independence enables a long-term vision and gives us the freedom to make our own strategic decisions.

We are committed to therapeutic progress to service patient needs and driven by a bold ambition to double our revenue by 2030 by reaching €10 billion in sales.

We are present in all the key innovation ecosystems in the world with capabilities ranging from R&D, commercial and manufacturing.

This includes 6 R&D centers, 19 clinical development centers, 13 manufacturing sites and commercial capabilities across the globe.

We are convinced that combining internal and external innovation will enable us to respond to major therapeutic challenges.



**AMBITIOUS STRATEGY,  
STRONG FINANCIAL  
RESOURCES**

Governed by  
Foundation:  
long term &  
independent



**TRACK RECORD OF  
SUCCESS**

In building our  
oncology pipeline but  
now also focused on  
partnering in rare  
neurological disorders



**A RELIABLE, LONG-  
TERM PARTNER**

Interested in assets from  
late research through  
to late clinical



**PATIENTS AT THE HEART  
OF EVERYTHING WE  
DO**

Innovating for the  
benefit of patients

# DISCOVER SERVIER'S AREAS OF FOCUS FOR PARTNERING



**Oncology**



**Therapeutic modalities & technologies**



**AI & digital technologies applied to R&D**



**Neurology**



**Drug discoveries & development technologies**



**Digital, Data, AI & Beyond-the-Pill**

## SERVIER VENTURES



**Contact: Alexis Vandier**  
Global Head of Servier Ventures  
alexis.vandier@servier.com

### Our mission

Invest in biotech and technological companies shaping the future of oncology and neurology, expanding Servier's reach across the global innovation ecosystem to advance science and unlock tomorrow's breakthrough therapies for the benefit of patients.

#### Strategic Focus

#### Therapeutic focus:



#### Oncology

Oncology antibodies (mabs, ADCs, multi-specifics), small molecules



#### Neurology

rare neurological disorders, ASO

#### Investment scope:

#### Development stage:

Late Pre-IND (Late LO / CD)

#### Geography:

primarily Europe

#### Asset types:

High-unmet need, strong differentiation, first-in-class, best in class, technology platforms

#### Our value proposition



**Fund size**  
€200M, evergreen



**Commitment:**  
long-term capital, no fixed cycles



**Investment strategy:**  
minority equity investments of €5 to 10M, primarily in **Series A** financing rounds



**A committed partner:**  
selective access to Servier expertise & capabilities



**Network:**  
connection to Servier venture syndicates, incubators and ecosystem players



Expanding our **ONCOLOGY** pipeline to meet patient needs

We are expanding Servier's pipeline in selected oncology disease areas at all development stages, from research to late clinical.

PARTNERING INTERESTS

Key focus disease areas

PRIMARY	<b>LEUKEMIA</b> AML, ALL, MDS, MPNs	<b>BRAIN</b>	<b>GI</b> PDAC, CRC, BTC, Gastric, Esophageal, Others <sup>1</sup>	
	SECONDARY	<b>LUNG CANCER</b> Non small cell Lung	<b>RARE CANCERS</b>	<b>LYMPHOMA</b> NHL, HL
MODALITIES		<b>ANTIBODIES</b> (mAb, ADC, bi-tri specific, TCE)		<b>SMALL MOLECULES</b>

1. Others include but not limited to small intestine, anal, appendiceal, Gyn, GU, H&N, thyroid, thymoma.

Deal types

Global rights as a priority or regional (EU or US followed by China or Japan)

Late-stage clinical focus

Hematologic tumors (ALL, AML, MDS)  
Solid tumors (GI & CNS as a priority)

Discovery & early-stage clinical focus

Cancer cell targeting:

- Synthetic lethality
- Apoptosis
- Precision oncology
- Biomarker-defined populations

Immuno-oncology:

- Tumor immune micro-environment
- T-cell targeting

PARTNERING CONTACTS

Global BD



**Anne Dagallier, PhD**  
Global Head of Licensing Oncology  
anne.dagallier@servier.com



**Valérie Agrapart, PharmD**  
Director, Business Development Oncology  
valerie.agrapart@servier.com



**Alix Scholer-Dahirel, PhD**  
Director, Business Development Oncology  
alix.scholer-dahirel@servier.com



**Julie Legrand, PhD**  
Director, Business Development Oncology  
julie.legrand@servier.com

R&D Search& Evaluation



**Irene Blat, PhD**  
Senior Director, Search & Evaluation, Oncology  
irene.blat@servier.com



**Lianyu Guo, PhD**  
Director, Search & Evaluation, Oncology, China & South Korea  
lianyu.guo@servier.com



**Trinh Lam**  
Project Coordination Manager, Oncology  
trinh.lam@servier.com



**Cynthia Wang, MBA, MSc**  
Director, Business Development  
cynthia.wang@servier.com

**Global BD Operations**

**Local BD Asia-Pacific**



## Building an innovative pipeline in **NEUROLOGY**

Our ambition is to build a new franchise in Rare Neurological Disorders by 2030. Similar to oncology, we will concentrate on hard-to-treat diseases with high medical needs.

### PARTNERING INTERESTS

#### Key focus disease areas

PRIMARY		<b>RARE MOVEMENT DISORDERS<sup>1</sup></b> FA, SCA, MSA, PSP, HD		<b>NEUROMUSCULAR DISORDERS<sup>2</sup></b> ALS, SMA, DMD, FSHD, DM, MG		<b>REFRACTORY EPILEPSIES<sup>3</sup></b> DS, LGS, JS, WS, OTHER DEES	
	SECONDARY		<b>LEUKODYSTROPHIES</b>		<b>GENETICALLY DRIVEN ASD<sup>4</sup></b> PMD, RETT, AG		<b>PERIPHERAL NEUROPATHIES<sup>5</sup></b> CMT, CIDP
		MODALITIES		<b>ANTIBODIES</b>		<b>OLIGONUCLEOTIDES</b>	

1. FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease  
 2. ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Dystrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis  
 3. DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies  
 4. ASD: Autism Spectrum Disorders; PMD: Phelan McDermid Syndrome; AG: Angelman Syndrome  
 5. CMT: Charcot-Marie-Tooth; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

### PARTNERING CONTACTS

#### Global BD



**Marine Beurdeley**  
Global Lead  
Neurology  
marine.beurdeley@servier.com

#### R&D Search & Evaluation



**Camille Nicoleau, PhD**  
Director, Search &  
Evaluation, Neurology  
camille.nicoleau@servier.com



**David Theron**  
Project Director  
Neurology  
david.theron@servier.com



**Lianyu Guo, PhD**  
Director, Search & Evaluation,  
Neurology, China & South Korea  
lianyu.guo@servier.com

#### Local BD



#### Asia-Pacific

**Cynthia Wang, MBA, MSc**  
Director, Business  
Development  
cynthia.wang@servier.com



**Lara-Maria Matar**  
Project Coordination  
Manager, Neurology  
laramaria.matar@servier.com



## Therapeutic modalities & technologies

### PARTNERING INTERESTS

#### Small Molecules

- Kinase, PPI, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery; prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

#### Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

#### Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

### PARTNERING CONTACTS

#### R&D Search & Evaluation



**Georges Da Violante**  
 Director, Search & Evaluation,  
 Enabling Technologies  
[georges.da-violante@servier.com](mailto:georges.da-violante@servier.com)

#### Global BD Operations



**Delphine Duong**  
 Project Coordination Manager,  
 Research Transactions  
[delphine.duong@servier.com](mailto:delphine.duong@servier.com)

## Drug discovery & development technologies



### PARTNERING INTERESTS

#### Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a chip (liver, brain, kidney)

#### Protein sciences imaging

- High throughput functional & stability antibody screening
- Antigen specific immuno-oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput mass spectrometry based proteomic analysis approach
- Mass spectrometry target

#### Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms -multiplexing, spatial multiomics strategy, spatial phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

#### Sample optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry based proteomic analysis approach

#### Liquid Biopsies

- Circulating tumor DNA (ctDNA) and methylation assay development
- Circulating tumor cells (CTC)
- Exosomes or extracellular vesicle extraction from blood for biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

#### Flow chemistry

- Multistep synthesis
- Photochemistry, electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallization/drying/milling
- In line analysis
- Continuous manufacturing in pharma



## AI & digital technologies applied to R&D

### PARTNERING INTERESTS

#### Focusing on a patient centered use of AI and digital technologies to:

- Enrich our pipeline by either developing first in class new drugs or by repurposing existing drugs
- Improve treatment effectiveness, reduce adverse effects and enhance patient outcomes
- Accelerate our drug discovery & development processes

#### Main thematic of our data analytics strategy:

##### Early research

- Target identification and validation, hit screening and validation, drug design, patient stratification

##### Late research

- Treatment understanding, DMTA cycle optimization, disease understanding, biomarker identification

### PARTNERING CONTACTS

#### R&D Search & Evaluation



**Franck Augé, PhD**  
**Director, Search & Evaluation, AI & Digital Technologies**  
 franck.auge@servier.com

#### Global BD Operations



**Delphine Duong**  
**Project Coordination Manager, Research Transactions**  
 delphine.duong@servier.com

#### Therapeutic modalities:

- Small molecules, antisense oligonucleotides (ASO), antibodies (mAbs, bispecifics, ADCs)

##### Early development

- Disease modelling, optimization of clinical trial design, biomarker validation
- Drug product development & characterization

##### Late development

- Strategy for patient finding and site selection, optimization of medical authoring, patient-centric clinical trial execution, pharmacovigilance processes optimization

## Digital, Data, AI opportunities & Beyond-the-Pill solutions



### PARTNERING INTERESTS

#### Preferred digital & AI use cases

##### Initiatives focusing pharma operational efficiency & decision-making

- AI medical, health equity and patient insights management
- Sales forecasts, supply chain, manufacturing & employee optimization

##### Examples of solutions supporting health care professional (HCPs) activities

- Clinical decision support tools and clinical trials platform optimization
- Remote patient monitoring & dashboards

##### Examples of beyond-the-pill solutions supporting patients & caregivers

- Solutions supporting adherence (esp. chronic disease) & quality of life
- Patients journey insights and personalization (esp. oncology)
- Solutions offering education and gamification possibilities

### PARTNERING CONTACTS

#### Digital Factory Partnering Team



**Grégoire Guillet**  
**Chief Business & Value Officer**  
 gregoire.guillet@servier.com



**Véronique Frechin**  
**Chief Innovation Officer**  
 veronique.frechin@servier.com



**Claire Maze-Sencier**  
**E-Health Business Analyst**  
 claire.mazesencier@servier.com



**Marianne Schuler**  
**Scouting Officer**  
 marianne.schuler@servier.com

#### Preferred modalities

##### Geographic scope

- Worldwide (or regional)

##### Deal types

- Co-development, licenses, strategic partnerships & beyond

##### Preferred maturity stage & technical aspects

- Ready to use solutions
- Previous pharma partnerships
- Medical device (depending on use case)
- Clinical benefits targeted

**SERVIER**   
*moved by you*



**Partner with us.**